LeadPrysmNewsBlogDirectoryAgenciesProjectsNewPost a projectTry it free →
← All funding news
CE
Funding news
18 November 2026

Celosia Therapeutics secures $2 million grant for MND gene therapies

Sydney-based biotech Celosia Therapeutics has secured $2 million from the NSW government's tech commercialisation fund to expand its motor neurone disease gene therapy pipeline.

Grant funding

Celosia Therapeutics announced on 18 November 2026 that it secured $2 million from the NSW government's tech commercialisation fund. The Sydney-based startup received the largest grant awarded in the first round of the NSW Emerging Technology Commercialisation Fund, which distributed $7 million across six startups. Celosia was the only applicant out of more than 250 businesses to receive the maximum grant amount.

The $20 million commercialisation fund operates over three years as part of the NSW Innovation Blueprint 2035.

Gene therapy development

Celosia Therapeutics is a Macquarie University spinout developing gene therapy treatments for motor neurone disease (MND). The biotech grew out of research by Macquarie University professors Lars Ittner and Yazi Ke into a protein named TDP-43.

In around 97% of amyotrophic lateral sclerosis (ALS) cases, the TDP-43 protein forms toxic clumps inside nerve cells. Celosia is developing therapies designed to help cells clear these toxic protein clumps while preserving healthy protein function.

The company's lead program, CTx1000, targets sporadic ALS, the most common form of MND. In March, Celosia stated that the first participant in a phase 1b trial assessing the safety and tolerability of a single dose of CTx1000 had received the treatment.

Use of funds

The grant funding will be used to expand the company's MND pipeline, supporting candidate development, preclinical studies, and manufacturing work alongside its lead CTx1000 program.

Celosia will work with the NSW Viral Vector Manufacturing Facility over two years to create a process to reliably produce the new therapy in larger quantities and test its quality ahead of future clinical studies, according to CEO Dr Kathryn Sunn.

Prior backing

Celosia previously raised $16.75 million in a 2024 Series A round led by Uniseed. The funding round also included backing from Iomar Barrett, who was living with ALS.

Sources

How we report: this story was written with AI assistance from the company's announcement and the sources above, and every figure in it was checked against them before publication. Spotted an error? Tell usand we'll fix it.

More funding news
€3.2 million · Seed · Cork
ArrayPatch raises €3.2m seed funding to advance drug delivery patches
$2.7 Mn · Pre-Seed · Bengaluru
Venomics AI Raises $2.7 Million Pre-Seed Round For Venom-Based Drug Discovery
$5 million · Seed+ · Montreal
DropGenie raises $5 million seed round to scale functional biology platform
$500k · Pre-Seed · Lagos
Lagos-based Khaime raises $500k pre-seed round led by Launch Africa Ventures